Dark Pools used to manipulate spreads
"Dark pools started in the 1980s when some institutional investors got together to trade in a place where they could avoid the prying eyes of public exchanges or brokers. They wanted to be able to buy or sell large quantities of stocks without affecting the market and thus get better execution prices.
Around 2005 these dark pools only made up 3%-5% of market activity.
Then things started changing in 2007, when the SEC passed new regulations known as Reg NMS (Regulation National Market System).
In Reg NMS were provisions that seriously upped competition for the exchanges. For one, it got rid of rules that protected manual quotations by exchanges. All of the sudden investors had the option of skipping exchanges if they could find a better price more quickly elsewhere.
Broker-dealers saw an opportunity in this (and in the rise of automated trading), and they started setting up their own dark pools. Institutional investors and bulge bracket banks started heading over to them to save on trading costs.
Today trading in dark pools accounts for about 12% of volume in the US.
Ultimately, the key benefit of trading in the dark pool is "price improvement". Say the bid for a stock on an exchange is $10.00, and the first asking price is $10.10. A typical dark pool will set the price at $10.05, the midpoint between the bid and the ask.
And traders like that. No, they love that."
PRM's drug worked equally well without Jakafi, pointing to the fact that Jakafi is really a useless therapy overall. It would be interesting to see a comparison study between Imet & PRM-151 but neither are approved yet.
$1billion, $1trillion, people are desensitized to numbers Maine.
Up until GERN announced their partnership with J&J, INCY owned this space.
Promedior's PRM-151, sort of where IMET was over a year ago using only 27 patient data, has just received fast track on top of orphan drug designations and was used in combo testing with ruxolitinib "PRM-151 was safe and well tolerated on weekly and monthly dosing schedules, both alone and in combination with ruxolitinib, with no evidence of myelosuppression"
My impression is that Promedior's wheels were greased by certain lobbyists at the FDA to get their designation as fast as they did. Without a big brother backing GERN the shorts would have run the company into the ground. Scarlet probably knowing this seeked out a stronger partner. With J&J GERN is in a much bigger league of FDA lobbyists and have sig. more clout on panel reviews to get such special status approval.
I wonder if/when Promedior's announcement of partnership with INCY will be made public.
"Recent CandleStick Analysis
Dec-16-2014 Homing Pigeon
Dec-15-2014 Bearish Engulfing "
much better than last week's golden shower.
from American Bulls
"Compare the pattern’s strength and reliability with the market to help you in your buying decisions.
BULLISH HARAMI CROSS
This is a major bullish reversal pattern, which is even more significant than a regular Bullish Harami. The outline again looks like a pregnant woman, as with the Bullish Harami Pattern. However, now the baby is a Doji. Basically, the pattern is characterized by a black body followed by a Doji that is completely inside the range of the prior black body.
1. The market is characterized by a prevailing downtrend.
2. A black body is observed on the first day.
3. The Doji that is formed on the second day is completely engulfed by the body of the first day.
Pattern Requirements and Flexibility
The Bullish Harami Cross consists of two candlesticks, in which the body of the first black candlestick engulfs the body of the following Doji. The body of the first candlestick may be short.
A bearish mood prevails in the market, and a downtrend is in progress. The first day’s candlestick is a black body, which further supports bearishness. However the next day, prices open higher than the close, or at the close of the preceding day. The short traders are alarmed which leads to the covering of many short positions, causing the price to rise further. Moreover, the day closes at the opening price, showing lack of decision among traders. The increasing level of indecision and uncertainty amplifies the likelihood of a trend change and cause a reversal."
like I said earlier Promedior was working with combo therapies using ruxolitinib combos and by itself...see phase 2 results below. It very well could have been the INCY lobby behind their trial advancements and what looks to be less impressive using a smaller sample base but never the less still very promising test results when compared to GERON's trials.
Would like it if Irish could weigh in on their drug. She must have heard of it via the MPN forum.
they even have their own "public" poster girl.
Voncille Fryou, Patient F, tells her story.
"It’s rare that we get to see and hear one of our own, a patient step out from the PowerPoint the charts and graphs of a clinical trial report and tell us her story. Here’s Voncille. If you follow the rows of the chart, above, you’ll find Patient F, second from the bottom. Reading across you can see she’s the PRM-151 Poster Girl not for any dramatic change in counts — they mostly held steady except her MPN-SAF score, her total symptom score, is on an upward trend line. She seems to have had a bone marrow response, reversal of fibrosis. As Dr. Verstovsek cautions, all bone marrow data is provisional until the blinded review is completed. What isn’t provisional is Voncille’s spirit and willingness to share her experience. "
yeah that misnomer had to be clarified earlier. It was Mayo 1ST in that it was First in class drug study using Imet. but actually was phase 2 study.
"In January 2011, GERON initiated a Phase 2 clinical trial of imetelstat in patients with ET. The Phase 2 ET trial was a multi-center, single arm, and open-label trial that we designed to provide proof-of-concept for the potential use of imetelstat as a treatment for hematologic myeloid malignancies, including MF, MDS and AML. The trial leveraged clinical observations from Phase 1 trials suggesting that imetelstat reduces platelet counts, as well as non-clinical observations that imetelstat distributes well to bone marrow in rodent models and selectively inhibits the proliferation of malignant progenitors ex vivo from patients with ET. Hematologic responses were measured by reductions in platelet counts, and molecular responses were measured by reductions in the JAK2 V617F mutant allele burden in circulating granulocytes as assessed by reduction in the proportion of the abnormal Janus kinase 2, or JAK2, gene compared to the normal, or wild type JAK2 gene. We believe a decrease in the proportion of the JAK2 V617F mutant relative to the wild type JAK2 is consistent with selective inhibition of the malignant progenitor cells responsible for the disease."
your right Taz, I missed it earlier; only seeing orphan designation.
Nov.3 2014 The FDA granted fast track designation to PRM-151 as a potential treatment for patients with myelofibrosis, the drug’s manufacturer announced.
Highlights from ASH 2014
Highlights from ASCO 2014
Leukemia Resource Center
Highlights from HemOnc Today Melanoma and Cutaneous Malignancies
The designation encompasses three indications: primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Didn't Chippy closed down the Menlo site pretty well? He uses it for a Porsche parking lot. He was waiting for a deal like Janssen to move this fwd. not having in house facilities of his own anymore to pursue clinical testing.
U were right he did not seem pumped on pursuing fast tracked earlier last year. Don't know if things have changed with J&J on board but this space s getting some other action.
Promedior reports that the preliminary Phase 2 data for PRM-151 were presented for 27 patients with myelofibrosis, 18 of whom completed 24 weeks of therapy. PRM-151 demonstrated a 50% reduction in symptoms according to the MPN-SAF2 Total Symptom Score in 7 patients, 5 of which have persisted for 12 weeks and are therefore confirmed IWG-MRT3 Clinical Improvement symptom responses; 5 reductions in bone marrow fibrosis by 1 grade, with 2 of 3 patients confirmed 12 weeks later and 2 patients pending confirmatory biopsy; a 20% reduction in spleen volume reduction in 5 patients with one 50% reduction lasting 8 weeks; and improvements in hemoglobin and platelets. Each treatment group demonstrated improvements that met the pre-specified efficacy criteria for further exploration of PRM-151 in the second stage of this adaptive Phase 2 trial. Fifteen out of 18 patients who have completed the 24 week study are continuing treatment in a study extension.
In this study, PRM-151 was safe and well tolerated on weekly and monthly dosing schedules, both alone and in combination with ruxolitinib, with no evidence of myelosuppression. Most adverse events observed in the study were Grade 1 or 2 and considered unrelated to PRM-151. Overall, there were 14 severe adverse events (SAEs) in 5 study patients, including 3 deaths, 2 from pneumonia and 1 from progressive multi-organ failure. Other SAEs were abdominal pain, bone marrow biopsy site hematoma, sialadenitis, gastroenteritis and respiratory syncytial virus. The Company expects to report the complete first stage results of this ongoing Phase 2 study by the end of 2014.
This Phase 2 trial is a multi-center, two stage, adaptive design study to determine the efficacy and safety of PRM-151 as a single agent or added to a stable dose of ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF). 27 patients were enrolled in the first stage of the study;"
PRM-151 still has to run phase 2 stage studies. About as advanced as GERON in the development phase. PRM-151 has Orphan Designation in the US and EU for treatment of IPF and in the US for the treatment of myelofibrosis — a type of myeloproliferative neoplasm — a serious, life-limiting cancer that is characterized by fibrosis of the bone marrow.
" Phase 1b clinical trial was a randomized, double-blind, placebo-controlled study in 21 patients with IPF. Promedior measured the impact on bone marrow health, according to a scoring system that takes various side effects like spleen size and anemia into account (officially called the Myoproliferative Neoplasm Symptom Assessment Form). Seven out of the 18 patients had a 50 percent reduction in that score, and 5 of them saw their fibrosis reduced by at least one grade. A “number” of the patients on PRM-151 saw their levels of platelets and hemoglobin improve, though Bruhn wouldn’t specify how many. She says most of the side effects patients experienced were mild" The drug is based on a natural human protein so toxicity isn't an issue.
hope not...I hated the last weak week of trading we went through. I was sure that our psychopathic pig farmer MM was taking us down to fill that $2.40-$2.70 gap.
because it's not $4.03 it's $2.96. In a perfect world we'd all be hedge fund owners discussing where on St Bart's we'd be spending Christmas.